Tokyo, Aug. 5 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062446) titled 'A single-center retrospective study on clinical outcomes after the introduction of caplacizumab for thrombotic thrombocytopenic purpura and an exploratory analysis of risk factors for the ADAMTS13 inhibitor boosting' on Aug. 3.
Study Type:
Observational
Primary Sponsor:
Institute - Department of Hematology and Oncology, Graduate School of Medicine, Mie University
Condition:
Condition - Thrombotic thrombocytopenic purpura
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - The objective of this study is to comprehensively characterize the clinical characteristics, treat...